Powles, T., Eder, J.P., Fine, G.D., Braiteh, F.S., Loriot, Y., Cruz, C., et al. (2014) MPDL3280A (Anti-PD-L1) Treatment Leads to Clinical Activity in Metastatic Bladder Cancer. Nature, 515, 558-562.
http://dx.doi.org/10.1038/nature13904

has been cited by the following article:

• TITLE: Overview of Research and Development for Anticancer Drugs

  AUTHORS: Junjie Xu, Wenwei Mao

  KEYWORDS: Anticancer Drugs, Research and Development, Target Therapy, Phenotype Targeting, Anti-Tumor Immunity

  JOURNAL NAME: Journal of Cancer Therapy, Vol.7 No.10, October 21, 2016

  ABSTRACT: Anticancer drugs research and development have been the largest market area in the pharmaceutical industry in terms of the number of project, clinical trials and spending. In the last 10 - 30 years, targeting therapy for cancers has been developed and achieved enormous clinical effectiveness by transforming some previously deadly malignancies into chronically manageable conditions, but cure problem still remains. This mini review outlined the current status of anticancer drugs development and hinted the opinions of how to further increase the accuracy and efficacy of discovery for cancer treatment.